Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine
about
Human immunodeficiency virus & cardiovascular riskEffects of Zidovudine Treatment on Heart mRNA Expression and Mitochondrial DNA Copy Number Associated with Alterations in Deoxynucleoside Triphosphate Composition in a Neonatal Rat ModelTenofovir renal toxicity targets mitochondria of renal proximal tubules.Heart failure in patients with human immunodeficiency virus infection: epidemiology, pathophysiology, treatment, and future research.Transgenic cardiac-targeted overexpression of human thymidylate kinaseIn utero exposure of female CD-1 Mice to AZT and/or 3TC: I. Persistence of microscopic lesions in cardiac tissue.Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transportersAzidothymidine-triphosphate impairs mitochondrial dynamics by disrupting the quality control system.Aging and HIV/AIDS: pathogenetic role of therapeutic side effectsHuman immunodeficiency virus/acquired immunodeficiency syndrome and infertility: emerging problems in the era of highly active antiretrovirals.Mitochondrial toxicity and HIV therapy.Mitochondrial dna depletion, oxidative stress, and mutation: mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors.Cardiomyocytes undergo apoptosis in human immunodeficiency virus cardiomyopathy through mitochondrion- and death receptor-controlled pathwaysPlasma levels of brain natriuretic peptide: a potential marker for HIV-related cardiomyopathy.Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gamma hypothesis.Decreased mtDNA, oxidative stress, cardiomyopathy, and death from transgenic cardiac targeted human mutant polymerase gamma.Cardiac disease in transgenic mice expressing human immunodeficiency virus-1 nef in cells of the immune system.Targeted transgenic overexpression of mitochondrial thymidine kinase (TK2) alters mitochondrial DNA (mtDNA) and mitochondrial polypeptide abundance: transgenic TK2, mtDNA, and antiretrovirals.Azidothymidine (AZT) leads to arterial stiffening and intima-media thickening in mice.AZT-induced mitochondrial toxicity: an epigenetic paradigm for dysregulation of gene expression through mitochondrial oxidative stressDoes mitochondrial dysfunction during antiretroviral therapy in human immunodeficiency virus infection suggest antioxidant supplementation as a beneficial option?Mitochondrial polymerase gamma dysfunction and aging cause cardiac nuclear DNA methylation changes.Determinants of HIV-related cardiac disease among adults in north central Nigeria.Cardiac Dysfunction in HIV-1 Transgenic Mouse: Role of Stress and BAG3Skeletal and cardiac myopathy in HIV-1 transgenic ratsMurine cardiac mtDNA: effects of transgenic manipulation of nucleoside phosphorylation.Mitochondrial DNA impairment in nucleoside reverse transcriptase inhibitor-associated cardiomyopathyCardiac-targeted transgenic mutant mitochondrial enzymes: mtDNA defects, antiretroviral toxicity and cardiomyopathy.Long-term exposure to AZT, but not d4T, increases endothelial cell oxidative stress and mitochondrial dysfunction.Nucleoside reverse transcriptase inhibitor toxicity and mitochondrial DNA.Cardiovascular involvements in HIV-infected patients.HIV-1 transgene expression in rats induces differential expression of tumor necrosis factor alpha and zinc transporters in the liver and the lungAssociation of Tenofovir Use With Risk of Incident Heart Failure in HIV-Infected Patients.Depletion of the cellular antioxidant system contributes to tenofovir disoproxil fumarate - induced mitochondrial damage and increased oxido-nitrosative stress in the kidney.Management of immunosuppression and antiviral treatment before and after heart transplant for HIV-associated dilated cardiomyopathy.Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice.Targeted myocardial transgenic expression of HIV Tat causes cardiomyopathy and mitochondrial damage.Nucleoside reverse transcriptase inhibitors impair endothelium-dependent relaxation by increasing superoxide.Cocaine increases mortality and cardiac mass in a murine transgenic model of acquired immune deficiency syndrome.Transgenic mitochondrial superoxide dismutase and mitochondrially targeted catalase prevent antiretroviral-induced oxidative stress and cardiomyopathy.
P2860
Q22241184-2B3E0F33-54F2-473A-9EB5-10871DE9D1D8Q28389095-AA2293C9-856E-4034-B88C-AACD2337E542Q33416391-C86D5199-6A30-43E4-BD63-1640B8E18F0DQ33551302-BF76FD18-1A69-475A-8F91-29F566D85193Q33690295-25D5158E-E96D-4143-991A-DC3D72DDA039Q33839401-FDF00F4E-316C-4811-8978-3DA25AEAB620Q33845879-6BC2E259-03F2-4756-9AFE-85BF3B89373FQ33874792-1A4C2CA9-58CC-4237-AEC2-38A2D9EB50C7Q34089694-67F4380C-D804-4453-8DF9-0C8D98A1EAF6Q34196934-ABC8E72E-2DDC-49DD-8CE0-BDB3FA7B561EQ34279271-6541F6A1-9843-4C96-8A6D-A90B95BFE847Q34282667-97B4B242-BAF1-43F7-8B76-538806B6FF0AQ34393925-DB020DCF-5F8A-4752-B924-F9E5A53FCF7AQ34859039-89250FC1-3E4E-4CB7-89A3-40419690CE61Q35606742-94B48D9F-EE8B-45AA-A21C-EFD46F17F4D8Q35695170-4AA9DD08-1D6D-47B7-A4A7-323CA0EE1F9BQ35747440-38C292C1-0F1B-422C-B82D-F433BBDF296EQ35781380-D669EA8B-35A7-4C51-B109-AD041222443BQ35898156-FC1E1B89-48E4-491C-B336-B44CF1D2AA3CQ36122838-1B5BAECC-0A7A-4D0A-933F-2DC21ABAFD15Q36255314-4E13194E-FEF1-4276-AD65-FAB650DF1E34Q36775694-CE0F1724-A55A-4B0F-A95C-14BF62618D87Q36800815-478DD90A-A956-4B9D-B7D6-0763AEC7CB15Q36827162-AF975548-1EA1-4E64-A42C-142D97518DCCQ36956010-562B045C-0082-435D-B407-59201DB8100AQ37199813-59D172CA-1E4B-4023-93CD-A4805E9E4E38Q37239515-A02D3DA4-EE9C-4177-85ED-D84A6CAC2CD7Q37239825-5C515F1F-BAAE-4E31-B952-6441E8959978Q37270571-60C77B32-763E-4F09-95F0-08AF483BA299Q37798546-48449C84-099F-47F6-A592-8F55DFF9DFB2Q38131061-93385571-9D31-4631-B116-8FCAE52F5427Q38867520-EFFEE814-12DE-499C-ADD2-AF1329E5F935Q40229714-86D01CB1-808F-46EB-87F8-C71194455C04Q42588985-833C81B8-82C0-4298-AAE1-A35F266F3A99Q43584691-26227137-6AD4-461D-9394-DBF7288ABF50Q43797774-872414C1-14B3-45BD-9F9D-BF21084F1EFAQ43963405-B3C93A57-1201-4ACB-A7AD-F61EEA42584EQ44185615-6AF2F1F2-1A33-491B-8FEA-C12009749B7BQ44513283-C0C8D724-BF4E-4A97-977B-8E57A5CD749FQ46034270-E53C02C9-9323-4FE9-BEA1-41FF1C49C3A5
P2860
Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine
@ast
Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine
@en
Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine
@nl
type
label
Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine
@ast
Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine
@en
Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine
@nl
prefLabel
Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine
@ast
Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine
@en
Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine
@nl
P2093
P2860
P1476
Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine
@en
P2093
A M Samarel
L Bruggeman
P2860
P2888
P304
P356
10.1038/LABINVEST.3780022
P407
P577
2000-02-01T00:00:00Z
P5875
P6179
1026084534